Cargando…

The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis

OBJECTIVE: To determine whether reliable brain atrophy measures can be obtained from post-contrast 3D T1-weighted images in patients with multiple sclerosis (MS) using FreeSurfer. METHODS: Twenty-two patients with MS were included, in which 3D T1-weighted MR images were obtained during the same scan...

Descripción completa

Detalles Bibliográficos
Autores principales: Lie, Ingrid Anne, Kerklingh, Emma, Wesnes, Kristin, van Nederpelt, David R., Brouwer, Iman, Torkildsen, Øivind, Myhr, Kjell-Morten, Barkhof, Frederik, Bø, Lars, Vrenken, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038813/
https://www.ncbi.nlm.nih.gov/pubmed/34978580
http://dx.doi.org/10.1007/s00330-021-08405-8
_version_ 1784693985667710976
author Lie, Ingrid Anne
Kerklingh, Emma
Wesnes, Kristin
van Nederpelt, David R.
Brouwer, Iman
Torkildsen, Øivind
Myhr, Kjell-Morten
Barkhof, Frederik
Bø, Lars
Vrenken, Hugo
author_facet Lie, Ingrid Anne
Kerklingh, Emma
Wesnes, Kristin
van Nederpelt, David R.
Brouwer, Iman
Torkildsen, Øivind
Myhr, Kjell-Morten
Barkhof, Frederik
Bø, Lars
Vrenken, Hugo
author_sort Lie, Ingrid Anne
collection PubMed
description OBJECTIVE: To determine whether reliable brain atrophy measures can be obtained from post-contrast 3D T1-weighted images in patients with multiple sclerosis (MS) using FreeSurfer. METHODS: Twenty-two patients with MS were included, in which 3D T1-weighted MR images were obtained during the same scanner visit, with the same acquisition protocol, before and after administration of gadolinium-based contrast agents (GBCAs). Two FreeSurfer versions (v.6.0.1 and v.7.1.1.) were applied to calculate grey matter (GM) and white matter (WM) volumes and global and regional cortical thickness. The consistency between measures obtained in pre- and post-contrast images was assessed by intra-class correlation coefficient (ICC), the difference was investigated by paired t-tests, and the mean percentage increase or decrease was calculated for total WM and GM matter volume, total deep GM and thalamus volume, and mean cortical thickness. RESULTS: Good to excellent reliability was found between all investigated measures, with ICC ranging from 0.926 to 0.996, all p values < 0.001. GM volumes and cortical thickness measurements were significantly higher in post-contrast images by 3.1 to 17.4%, while total WM volume decreased significantly by 1.7% (all p values < 0.001). CONCLUSION: The consistency between values obtained from pre- and post-contrast images was excellent, suggesting it may be possible to extract reliable brain atrophy measurements from T1-weighted images acquired after administration of GBCAs, using FreeSurfer. However, absolute values were systematically different between pre- and post-contrast images, meaning that such images should not be compared directly. Potential systematic effects, possibly dependent on GBCA dose or the delay time after contrast injection, should be investigated. TRIAL REGISTRATION: Clinical trials.gov. identifier: NCT00360906. KEY POINTS: • The influence of gadolinium-based contrast agents (GBCAs) on atrophy measurements is still largely unknown and challenges the use of a considerable source of historical and prospective real-world data. • In 22 patients with multiple sclerosis, the consistency between brain atrophy measurements obtained from pre- and post-contrast images was excellent, suggesting it may be possible to extract reliable atrophy measurements in T1-weighted images acquired after administration of GBCAs, using FreeSurfer. • Absolute values were systematically different between pre- and post-contrast images, meaning that such images should not be compared directly, and measurements extracted from certain regions (e.g., the temporal pole) should be interpreted with caution. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08405-8.
format Online
Article
Text
id pubmed-9038813
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-90388132022-05-07 The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis Lie, Ingrid Anne Kerklingh, Emma Wesnes, Kristin van Nederpelt, David R. Brouwer, Iman Torkildsen, Øivind Myhr, Kjell-Morten Barkhof, Frederik Bø, Lars Vrenken, Hugo Eur Radiol Neuro OBJECTIVE: To determine whether reliable brain atrophy measures can be obtained from post-contrast 3D T1-weighted images in patients with multiple sclerosis (MS) using FreeSurfer. METHODS: Twenty-two patients with MS were included, in which 3D T1-weighted MR images were obtained during the same scanner visit, with the same acquisition protocol, before and after administration of gadolinium-based contrast agents (GBCAs). Two FreeSurfer versions (v.6.0.1 and v.7.1.1.) were applied to calculate grey matter (GM) and white matter (WM) volumes and global and regional cortical thickness. The consistency between measures obtained in pre- and post-contrast images was assessed by intra-class correlation coefficient (ICC), the difference was investigated by paired t-tests, and the mean percentage increase or decrease was calculated for total WM and GM matter volume, total deep GM and thalamus volume, and mean cortical thickness. RESULTS: Good to excellent reliability was found between all investigated measures, with ICC ranging from 0.926 to 0.996, all p values < 0.001. GM volumes and cortical thickness measurements were significantly higher in post-contrast images by 3.1 to 17.4%, while total WM volume decreased significantly by 1.7% (all p values < 0.001). CONCLUSION: The consistency between values obtained from pre- and post-contrast images was excellent, suggesting it may be possible to extract reliable brain atrophy measurements from T1-weighted images acquired after administration of GBCAs, using FreeSurfer. However, absolute values were systematically different between pre- and post-contrast images, meaning that such images should not be compared directly. Potential systematic effects, possibly dependent on GBCA dose or the delay time after contrast injection, should be investigated. TRIAL REGISTRATION: Clinical trials.gov. identifier: NCT00360906. KEY POINTS: • The influence of gadolinium-based contrast agents (GBCAs) on atrophy measurements is still largely unknown and challenges the use of a considerable source of historical and prospective real-world data. • In 22 patients with multiple sclerosis, the consistency between brain atrophy measurements obtained from pre- and post-contrast images was excellent, suggesting it may be possible to extract reliable atrophy measurements in T1-weighted images acquired after administration of GBCAs, using FreeSurfer. • Absolute values were systematically different between pre- and post-contrast images, meaning that such images should not be compared directly, and measurements extracted from certain regions (e.g., the temporal pole) should be interpreted with caution. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08405-8. Springer Berlin Heidelberg 2022-01-03 2022 /pmc/articles/PMC9038813/ /pubmed/34978580 http://dx.doi.org/10.1007/s00330-021-08405-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Neuro
Lie, Ingrid Anne
Kerklingh, Emma
Wesnes, Kristin
van Nederpelt, David R.
Brouwer, Iman
Torkildsen, Øivind
Myhr, Kjell-Morten
Barkhof, Frederik
Bø, Lars
Vrenken, Hugo
The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
title The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
title_full The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
title_fullStr The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
title_full_unstemmed The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
title_short The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
title_sort effect of gadolinium-based contrast-agents on automated brain atrophy measurements by freesurfer in patients with multiple sclerosis
topic Neuro
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038813/
https://www.ncbi.nlm.nih.gov/pubmed/34978580
http://dx.doi.org/10.1007/s00330-021-08405-8
work_keys_str_mv AT lieingridanne theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT kerklinghemma theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT wesneskristin theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT vannederpeltdavidr theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT brouweriman theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT torkildsenøivind theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT myhrkjellmorten theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT barkhoffrederik theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT bølars theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT vrenkenhugo theeffectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT lieingridanne effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT kerklinghemma effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT wesneskristin effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT vannederpeltdavidr effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT brouweriman effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT torkildsenøivind effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT myhrkjellmorten effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT barkhoffrederik effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT bølars effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis
AT vrenkenhugo effectofgadoliniumbasedcontrastagentsonautomatedbrainatrophymeasurementsbyfreesurferinpatientswithmultiplesclerosis